Mark C. Lanasa
Impact in
- Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research
- Immunology top 2%
- Immunodeficiency and Autoimmune Disorders
- Immune Cell Function and Interaction
Papers in
- Genetics 55
- Chronic Lymphocytic Leukemia Research 55
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities 6
-
- Lymphoma Diagnosis and Treatment 27
- Co-authors
- William Allen Hogge (6 shared papers)Tait D. Shanafelt (7 shared papers)Paolo Ghia (4 shared papers)Andy C. Rawstron (3 shared papers)J. Brice Weinberg (21 shared papers)Ola Landgren (2 shared papers)Urvashi Surti (2 shared papers)Eric Hoffman (4 shared papers)
- Journals
- Blood (23 papers)Leukemia (6 papers)Annals of Oncology (4 papers)British Journal of Haematology (4 papers)The American Journal of Human Genetics (3 papers)
- Partner nations
- United StatesUnited KingdomItaly
In The Last Decade
Mark C. Lanasa
74 papers receiving 3.4k citations
Mark C. Lanasa's Hit Papers
Peers
Comparison fields: 5 of 90
- Genetics 1.3k
- Immunology 1.2k
- Pathology and Forensic Medicine 933
- Oncology 1.2k
- Hematology 224
Countries citing papers authored by Mark C. Lanasa
This map shows the geographic impact of Mark C. Lanasa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark C. Lanasa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark C. Lanasa more than expected).
Fields of papers citing papers by Mark C. Lanasa
This network shows the impact of papers produced by Mark C. Lanasa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark C. Lanasa. The network helps show where Mark C. Lanasa may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark C. Lanasa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 74 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study Hit paper breakdown → | 2020 | 380 |
| 2 | 2021 | 172 | |
| 3 | 2010 | 172 | |
| 4 | 2013 | 167 | |
| 5 | 2012 | 147 | |
| 6 | 2010 | 133 | |
| 7 | 1997 | 117 | |
| 8 | 2018 | 117 | |
| 9 | 2010 | 109 | |
| 10 | 2003 | 105 | |
| 11 | 2011 | 103 | |
| 12 | 2010 | 89 | |
| 13 | 2019 | 84 | |
| 14 | 2018 | 83 | |
| 15 | 2013 | 81 | |
| 16 | 2009 | 77 | |
| 17 | 2020 | 76 | |
| 18 | 2019 | 72 | |
| 19 | 2012 | 65 | |
| 20 | 2018 | 61 |
About Mark C. Lanasa
Mark C. Lanasa is a scholar working on Genetics, Pathology and Forensic Medicine, Immunology, Oncology and Genetics, having authored 74 papers that have together received 3.5k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (55 papers), Lymphoma Diagnosis and Treatment (27 papers), Immunodeficiency and Autoimmune Disorders (23 papers), Acute Lymphoblastic Leukemia research (6 papers), Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities (6 papers), PARP inhibition in cancer therapy (5 papers), Advanced Breast Cancer Therapies (5 papers) and Cancer-related Molecular Pathways (4 papers). The work is most often cited by research in Genetics (1.3k citations), Immunology (1.2k citations), Pathology and Forensic Medicine (933 citations), Oncology (1.2k citations) and Hematology (224 citations). Mark C. Lanasa has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include William Allen Hogge, Tait D. Shanafelt, Paolo Ghia, Andy C. Rawstron, J. Brice Weinberg, Ola Landgren, Urvashi Surti, Eric Hoffman, Jon P. Gockerman and Alicia D. Volkheimer. Their work appears in journals such as Blood, Leukemia, Annals of Oncology, British Journal of Haematology and The American Journal of Human Genetics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.